Circular No. 20/2020/TT-BYT amends and supplements certain provisions of Circular No. 30/2018/TT-BYT dated October 30, 2018, issued by the Minister of Health on the List and payment ratio for chemical drugs, biological products, radioactive drugs, and labeling substances within the scope of health insurance coverage.

Circular No. 20/2020/TT-BYT amends and supplements certain provisions of Circular No. 30/2018/TT-BYT regarding the list and payment ratio for chemical drugs, biological products, radioactive drugs, and labeling substances within the scope of health insurance. Notably, this circular adds the drug Tenofovir + lamivudine + dolutegravir to the list.

Số hiệu20/2020/TT-BYT
Loại văn bảnCircular
Cơ quan ban hànhMinistry of Health
Người kýNguyễn Trường Sơn — Thứ trưởng
Cập nhật14/06/2026
NgànhHealth
Lĩnh vựcHealth Insurance
Ngày ban hành26/11/2020
Ngày áp dụng15/01/2021
Ngày hết hiệu lực01/03/2023
Tình trạngExpired
✦ Tóm lược thông minh

Circular No. 20/2020/TT-BYT amends and supplements certain provisions of Circular No. 30/2018/TT-BYT regarding the list and payment ratio for chemical drugs, biological products, radioactive drugs, and labeling substances within the scope of health insurance. Notably, this circular adds the drug Tenofovir + lamivudine + dolutegravir to the list.

Đối tượng áp dụng

Health insurance participants; healthcare facilities and medical service providers

Các điểm cốt lõi

  • Medicines with active ingredients listed in Appendix 01 or Appendix 02 (Point a, Article 4)
  • Consistent with the route of administration, form, and hospital category according to the List in Appendix 01 or Appendix 02 (Point b, Article 4)
  • The drug Tenofovir + lamivudine + dolutegravir is added to the list of antiretroviral drugs for HIV/AIDS treatment (Article 2)
  • The new drug shall only be distributed at commune health stations in accordance with the Ministry of Health's guidelines on the management, treatment, and care of HIV/AIDS
  • This Circular takes effect from January 15, 2021

🌐 Tác động xã hội từ văn bản này

  • To expand the list of medicines covered by health insurance payments for patients, reducing financial burdens for citizens
  • To enhance the management and effective use of medicines in HIV/AIDS treatment

❓ Câu hỏi thường gặp

Where is the drug Tenofovir + lamivudine + dolutegravir distributed?

This drug shall only be distributed at commune health stations in accordance with the Ministry of Health's guidelines on the management, treatment, and care of HIV/AIDS.

When does this Circular take effect?

This Circular takes effect from January 15, 2021

Toàn văn

MINISTRY OF HEALTH

SOCIALIST REPUBLIC OF VIET NAM
Independence – Freedom – Happiness

Number: 20/2020/TT-BYT
Hanoi, November 26, 2020

CIRCULAR

AMENDMENTS AND SUPPLEMENTS TO CERTAIN ARTICLES OF THE CIRCULAR NO. 30/2018/TT-BYT DATED OCTOBER 30, 2018 ISSUED BY THE MINISTER OF HEALTH ON THE LIST AND RATES, CONDITIONS FOR PAYMENT OF CHEMICAL DRUGS, BIOPRODUCTS, RADIOACTIVE DRUGS, AND MARKERS WITHIN THE SCOPE OF BENEFITS FOR PARTICIPANTS IN HEALTH INSURANCE

Pursuant to the Health Insurance Law No. 25/2008/QH12 dated November 14, 2008, as amended and supplemented by Law No. 46/2014/QH13 dated June 13, 2014;

Pursuant to the Government's Decree No. 75/2017/NĐ-CP dated June 20, 2017 stipulating the functions, tasks, powers, and organizational structure of the Ministry of Health;

At the request of the Director of the Health Insurance Department,

The Minister of Health issues this Circular to amend and supplement certain articles of Circular No. 30/2018/TT-BYT dated October 30, 2018, issued by the Minister of Health on the List and Rates, Conditions for Payment of Chemical Drugs, Bioproducts, Radioactive Drugs, and Markers within the scope of benefits for participants in health insurance.

Article 1. Amend and supplement Points a and b of Clause 7, Article 4 of Circular No. 30/2018/TT-BYT dated October 30, 2018, issued by the Minister of Health on the List and Rates, Conditions for Payment of Chemical Drugs, Bioproducts, Radioactive Drugs, and Markers within the scope of benefits for participants in health insurance (hereinafter referred to as Circular No. 30/2018/TT-BYT) as follows:

a) Active substance of the drug included in the List at Appendix 01 or Appendix 02;

b) Consistent with the route of administration, form, and hospital category used in the List at Appendix 01 or Appendix 02.

Article 2. Supplement the drug Tenofovir + lamivudine + dolutegravir into Sub-subgroup 6.3.1 - Anti-HIV/AIDS drugs under Subgroup 6.3 - Antiviral drugs of Group 6 - Parasitic Treatment and Antibacterial Drugs in Appendix 01 of the List of Chemical Drugs and Bioproducts within the scope of benefits for participants in health insurance issued together with Circular No. 30/2018/TT-BYT as follows:

Serial number

Active Ingredient Name

Route of administration, form

Hospital category

Remarks

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

 

6. DRUGS FOR PARASITIC TREATMENT AND ANTI-INFECTIVE THERAPY

 

6.3. Antiviral drugs

 

6.3.1. Anti-HIV/AIDS drugs

270a

Tenofovir + lamivudine + dolutegravir

Oral

+

+

+

 

For HIV/AIDS treatment: The drug shall be dispensed at commune health stations according to the Ministry of Health's guidelines on HIV/AIDS management, treatment, and care.

Article 3. Effective Date.

This Circular takes effect from January 15, 2021.

In the course of implementation, if there are difficulties or obstacles, please reflect them in writing to the Ministry of Health for consideration and resolution../.

DEPUTY MINISTER
DEPUTY MINISTER
(Signed)
Nguyen Truong Son

Văn bản gốc (PDF)

Mở PDF trong tab mới ↗

Bản đồ quan hệ

Bấm vào một văn bản để mở. Viền đỏ = quan hệ làm thay đổi hiệu lực.